Blood Irradiation Market Size, Share, and Analysis by 2028

The blood irradiation market is projected to reach US$ 104.37 million by 2028 from US$ 65.15 million in 2021; it is expected to grow at a CAGR of 7.0% from 2022 to 2028.

The rising prevalence of communicable and noncommunicable disorders and increasing research and development drive the market growth. However, the high cost of blood irradiation restricts the market growth.

Blood irradiation is achieved by exposing the blood to at least 25 Gy (2500 cGy) of radiation in the center of the vessel, preventing the replication and engraftment of immunologically competent donor T leukocytes to the recipient. GvHD caused by transplants from donors is almost always fatal, so patients at risk should receive irradiated blood products as time and resources allow. Clinical indications, including acute leukemia, lymphoma, solid tumors receiving intensive chemotherapy or radiation therapy, exchange transfusions, organ transplant recipients, and preterm infants, require blood irradiation therapy. Patients affected by human immunodeficiency virus/acquired immunodeficiency syndrome do not require blood product irradiation as they have not been reported to be susceptible to post-transfusion graft-to-host disease.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Blood Irradiation Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Market Insights

Increase in Prevalence of Communicable and Noncommunicable Diseases Drives Market Growth

There is an increase in the number of incidence of communicable and noncommunicable diseases, including cancer, cardiovascular disorders, chronic renal disease, and stroke, owing to a large population across the world susceptible to such conditions. According to World Health Organization (WHO), cardiovascular disorders are the leading cause of death globally, and ~17.9 million deaths are reported yearly. Additionally, the rising prevalence of communicable diseases, such as Hepatitis, influenza, Human Immunodeficiency Virus (HIV), and acquired immunodeficiency syndrome (AIDS), are driving the growth of the blood irradiation market. According to WHO, 325 million people were infected with the hepatitis B virus in 2020, and 900,000 people die from hepatitis B virus infection every year. Moreover, a large geriatric population across the world is contributing to the prevalence of noncommunicable diseases, such as cardiovascular disorders, renal disorders, and strokes. According to WHO, the population of people aged 60 years and above was 1 billion in 2019 and is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The elderly population is susceptible to noncommunicable disease conditions owing to various factors such as poor nutrition, lack of physical activity, excessive use of tobacco, and consumption of alcohol.

Additionally, surging blood transfusion owing to an increase in surgical procedures, accidents, trauma cases, and disorders, along with the rising prevalence of bloodstream infections, supports the market growth. Bloodstream infections, underlying conditions, and invasive procedures are common among the geriatric population. Bloodstream infections are the major cause of illness and death among large populations. According to the National Library of Medicine, ~28,000 bloodstream infections occur across the world annually. Moreover, rising awareness about bloodstream infections and increasing immune responses to transfused blood can cause complications as increasing use of irradiated blood in cancer treatment strengthens the immune system and improves overall health of patients, which is driving the growth of the blood irradiation market.

Thus, the increase in the prevalence of communicable and noncommunicable disorders, rise in blood transfusion, surge in bloodstream infections, and increase in immune responses are driving the growth of the blood irradiation market.

Type-Based Insights

The blood irradiation market, based on type, is segmented into intravenous laser blood irradiation , transcutaneous laser blood irradiation,and extracorporeal blood irradiation. In 2021, the intravenous laser blood irradiation segment accounted for the largest market share. However, the extracorporeal laser blood irradiation segment is expected to register the highest CAGR of 7.8% during the forecast period.

End User-Based Insights   

Based on end user, the blood irradiation market is segmented into hospitals, blood banks, diagnostics clinics, and research institutes. The hospitals segment held the largest market share in 2021. However, the blood banks segment is estimated to register the highest CAGR of 7.7% in the market during the forecast period.

Blood Irradiation Market Regional Insights

The regional trends and factors influencing the Blood Irradiation Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Blood Irradiation Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Blood Irradiation Market Report Scope

Blood Irradiation Market Players Density: Understanding Its Impact on Business Dynamics

The Blood Irradiation Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Blood Irradiation Market are:

1. Typenex Medical, LLC
2. Hitachi Medical Systems
3. Rad Source Technologies
4. Gilardoni S.p.A.
5. Gamma-Service Medical GmbH

Disclaimer: The companies listed above are not ranked in any particular order.

Indication-Based Insights

By indication, the blood irradiation market is segmented into acute leukemia, solid tumors, pelvic tumors, lymphoma, and others. The acute leukemia segment held the largest market share in 2021. However, the lymphoma segment is estimated to register the highest CAGR of 8.8% in the market during the forecast period.

Companies operating in the blood irradiation market adopt the product innovation strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market. For instance, in June 2021, Rad Source Technologies, a commercial X-ray radiation products supplier in the US, designed a product to replace self-shielded gamma irradiators and introduced its newly redesigned RS 3400 Blood Irradiator at MEDLAB Middle East 2021.

Blood Irradiation Market – by Geography

Geographically, the blood irradiation market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).  Typenex Medical, LLC; Hitachi Medical Systems; Rad Source Technologies; Gilardoni S.p.A.; Gamma-Service Medical GmbH; Actemium; and Best Theratronics Ltd. are among the market participants included in the research study.